A combination of anti-PD-L1 antibodies, which target the Programmed Death 1 ligand expressed on a number of tumor types, and ibrutinib, a chemotherapy drug that targets B-cell cancers, suppressed tumor growth in several mouse models of cancer that normally do not respond to ibrutinib treatment, suggesting that the combination therapy may help treat solid tumors, lymphoma, and other blood cancers, according to a study.
↧